Guest
When considering expanding operations to include activities outside the previously certified scope, what is the most appropriate sequence? Should we create procedures and practices that are inconsistent with the certified scope or update the scope first, although in this situation we wouldn't yet have any procedures to support that wider scope and certainly no evidence to show they were being followed (yet).
What risk would my hospital be at if our SSD lost its ISO 13485 accreditation?
Thank you for the webinar and for taking the time to respond to my question. However, I wanted to follow up regarding your answer to my question: “Does a PMS Plan need to be prepared for the Technical File? Or can there be one, for example, for all Class IIb medical devices from a manufacturer?”
You mentioned that the PMS Plan has to be device-specific, but I am looking for some additional clarification. Could you please support this with a reference to any article from the MDR or a statement from the MDCG Guidance documents? My understanding is that the MDR indicates the PMS system is based on a PMS Plan, and it would be helpful to see the exact regulatory backing for your response.
Hello
Kindly ask for your advice in appropriate classification of medical device which is gel called to provide temporary protection to the surface of a typical surgical implant from the attachment of pathogens to the implant surface and the formation of a biofilm. Implant need to be coated with this gel before implantation. It has no drugs, no nanomaterials, manufactured without manufactured utilising tissues or cells of human or animal origin.
Thank you for your thought in advance
Hello, I am quite new to this area and I appreciate your opinion on the following issue.
My company is developing an implantable medical device that incorporates an ancillary medicinal substance (drug A), in which the drug action is secondary.
Adittionaly to the device, a second drug (drug B) will be administered systemically, reason why we are considering the medical device plus the drug B as a Therapeutic System.
The drug A was approved for clinical trials (for other medical condition) but is not in the market (the clinical trials ended because it showed no efficacy). The drug B is market-approved (oral formulation) but we need a systemic formulation that is not yet developed (we are planning a partnership with a pharmaceutical company responsible for this development).
My questions are:
Can we do a combined trial with the MD and the 2 drugs, once we need to validate the complete therapeutic system?
Can the drug A be directly approved for our clinical trial, once it was approved before for other clinical trials (by FDA)?
Thank you.
Hi,
We do supply packaged ASIC (application specific IC) to customer that manufacture medical devices. Our ASICs are not considered medical devices, and we have received ISO 13485 certification. Does this mean that we should also fulfill the requirements of ISO 14971? If yes, how can we evalaute the benefit of our components?
Regarding ISO 13485 clause 4.2.3, is it correct to consider this not applicable since we do not manufacture medical device, and we do not have medical device files?
Thank you.